Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction (STRIDERCan)
STRIDER Canada: A Randomized Controlled Trial of Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction (Canada)
Sponsor: University of British Columbia
Terminated
Trial terminated following Dutch DSMB recommendation for their Study
Other terminated trials from University of British Columbia
This PHASE2/PHASE3 trial investigates Fetal Growth Restriction (FGR) and Intrauterine Growth Restriction (IUGR) and is currently terminated or withdrawn. University of British Columbia leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
▶ Show 5 earlier versions
-
Jun 2019 — Mar 2020 [monthly]
Terminated PHASE2_PHASE3
Status: Suspended → Terminated
-
Aug 2018 — Jun 2019 [monthly]
Suspended PHASE2_PHASE3
Status: Recruiting → Suspended
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of British Columbia
For direct contact, visit the study record on ClinicalTrials.gov .